Muromonab-CD3 therapy for refractory rejections after liver transplantation: A single-center experience during two decades in Japan

Daisuke Ueda, Tomohide Hori, Justin H Nguyen, Shinji Uemoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/purpose: Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT. Methods: A total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid-resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated. Results: The recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end-stage liver disease or pediatric end-stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction. Conclusion: Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.

Original languageEnglish (US)
Pages (from-to)885-891
Number of pages7
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume17
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Muromonab-CD3
Liver Transplantation
Japan
End Stage Liver Disease
Therapeutics
Steroids
Pediatrics
Incidence

Keywords

  • Liver transplantation
  • Muromonab-CD3
  • OKT3
  • Retransplantation
  • Steroid-resistant rejection

ASJC Scopus subject areas

  • Hepatology
  • Surgery
  • Medicine(all)

Cite this

Muromonab-CD3 therapy for refractory rejections after liver transplantation : A single-center experience during two decades in Japan. / Ueda, Daisuke; Hori, Tomohide; Nguyen, Justin H; Uemoto, Shinji.

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 17, No. 6, 11.2010, p. 885-891.

Research output: Contribution to journalArticle

@article{9b1e12e86ddf4764b457ab5d58a7c397,
title = "Muromonab-CD3 therapy for refractory rejections after liver transplantation: A single-center experience during two decades in Japan",
abstract = "Background/purpose: Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT. Methods: A total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid-resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated. Results: The recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end-stage liver disease or pediatric end-stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction. Conclusion: Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.",
keywords = "Liver transplantation, Muromonab-CD3, OKT3, Retransplantation, Steroid-resistant rejection",
author = "Daisuke Ueda and Tomohide Hori and Nguyen, {Justin H} and Shinji Uemoto",
year = "2010",
month = "11",
doi = "10.1007/s00534-010-0288-y",
language = "English (US)",
volume = "17",
pages = "885--891",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Muromonab-CD3 therapy for refractory rejections after liver transplantation

T2 - A single-center experience during two decades in Japan

AU - Ueda, Daisuke

AU - Hori, Tomohide

AU - Nguyen, Justin H

AU - Uemoto, Shinji

PY - 2010/11

Y1 - 2010/11

N2 - Background/purpose: Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT. Methods: A total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid-resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated. Results: The recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end-stage liver disease or pediatric end-stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction. Conclusion: Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.

AB - Background/purpose: Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT. Methods: A total of 1415 LT patients were retrospectively evaluated, and 11 of the recipients received MCD3 therapy because of steroid-resistant rejections. The clinical factors before LT and before MCD3 therapy were investigated. Results: The recipients were retrospectively divided into two groups based on responses to MCD3 therapy, including their clinical courses after MCD3 therapy and their outcomes. The MCD3 therapy had positive effects in LT recipients with the following four factors: low score of model for end-stage liver disease or pediatric end-stage liver disease; earlier time point of the first incidence of rejection; more frequent steroid pulse therapy (SPT) within 2 weeks after LT; and the expression of CD3 in the peripheral blood before MCD3 introduction. Conclusion: Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.

KW - Liver transplantation

KW - Muromonab-CD3

KW - OKT3

KW - Retransplantation

KW - Steroid-resistant rejection

UR - http://www.scopus.com/inward/record.url?scp=79952198334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952198334&partnerID=8YFLogxK

U2 - 10.1007/s00534-010-0288-y

DO - 10.1007/s00534-010-0288-y

M3 - Article

C2 - 20458505

AN - SCOPUS:79952198334

VL - 17

SP - 885

EP - 891

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 6

ER -